ALKBH5-mediated NPC2 mRNA m⁶A demethylation promotes resistance to oxaliplatin in colorectal cancer.

ABSTRACT: Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related death. Oxaliplatin, a key platinum-based chemotherapy, significantly improves outcomes in CRC patients. Nevertheless, oxaliplatin resistance often emerges, leading to worse prognosis. Exploring new biomarkers and mechanisms of resistance is crucial for overcoming oxaliplatin resistance and enhancing therapeutic efficacy. Through bioinformatics analysis, high NPC2 expression was found to be associated with oxaliplatin resistance and poor prognosis in CRC patients. Moreover, NPC2 was highly expressed in CRC tissues, especially in metastatic CRC tissues. Additionally, the expression of N6-methyladenosine (m⁶A) demethylase ALKBH5 was elevated in oxaliplatin-resistant colorectal can

SUBMITTER: Wan P 

PROVIDER: S-EPMC12274260 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature